217 related articles for article (PubMed ID: 19158840)
21. Therapeutic potential of human-induced pluripotent stem cell-derived endothelial cells in a bleomycin-induced scleroderma mouse model.
Azhdari M; Baghaban-Eslaminejad M; Baharvand H; Aghdami N
Stem Cell Res; 2013 May; 10(3):288-300. PubMed ID: 23396195
[TBL] [Abstract][Full Text] [Related]
22. Systemic sclerosis.
Asano Y
J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
[TBL] [Abstract][Full Text] [Related]
23. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
24. Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
J Immunol; 2016 Oct; 197(8):3018-3028. PubMed ID: 27613696
[TBL] [Abstract][Full Text] [Related]
25. New insights on chemically induced animal models of systemic sclerosis.
Batteux F; Kavian N; Servettaz A
Curr Opin Rheumatol; 2011 Nov; 23(6):511-8. PubMed ID: 21857225
[TBL] [Abstract][Full Text] [Related]
26. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.
Servettaz A; Kavian N; Nicco C; Deveaux V; Chéreau C; Wang A; Zimmer A; Lotersztajn S; Weill B; Batteux F
Am J Pathol; 2010 Jul; 177(1):187-96. PubMed ID: 20508030
[TBL] [Abstract][Full Text] [Related]
27. Activation of pregnane X receptor inhibits experimental dermal fibrosis.
Beyer C; Skapenko A; Distler A; Dees C; Reichert H; Munoz L; Leipe J; Schulze-Koops H; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2013 Apr; 72(4):621-5. PubMed ID: 23291432
[TBL] [Abstract][Full Text] [Related]
28. A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel.
Jun JB; Kim JK; Na YI; Jang SM; Paik SS; Kim YH
Rheumatol Int; 2012 May; 32(5):1443-7. PubMed ID: 21448642
[TBL] [Abstract][Full Text] [Related]
29. Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma.
Kato A; Yutani M; Terao M; Kimura A; Itoi S; Murota H; Miyoshi E; Katayama I
Exp Dermatol; 2015 Aug; 24(8):585-90. PubMed ID: 25876794
[TBL] [Abstract][Full Text] [Related]
30. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma.
Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A
Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557
[TBL] [Abstract][Full Text] [Related]
31. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.
Kajii M; Suzuki C; Kashihara J; Kobayashi F; Kubo Y; Miyamoto H; Yuuki T; Yamamoto T; Nakae T
Clin Exp Immunol; 2011 Feb; 163(2):235-41. PubMed ID: 21091669
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma.
Kohno S; Endo H; Hashimoto A; Hayashi I; Murakami Y; Kitasato H; Kojima F; Kawai S; Kondo H
Biomed Pharmacother; 2006 Jan; 60(1):18-25. PubMed ID: 16337105
[TBL] [Abstract][Full Text] [Related]
34. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
35. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
Fuschiotti P; Medsger TA; Morel PA
Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
[TBL] [Abstract][Full Text] [Related]
36. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13.
Aliprantis AO; Wang J; Fathman JW; Lemaire R; Dorfman DM; Lafyatis R; Glimcher LH
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2827-30. PubMed ID: 17307869
[TBL] [Abstract][Full Text] [Related]
37. A novel bispecific antibody alleviates bleomycin-induced systemic sclerosis injury.
Yin Q; Pi X; Ren G; Liu Z; Liu H; Wang M; Hu C; Zhao H; Li D; Yin J
Int Immunopharmacol; 2020 Aug; 85():106644. PubMed ID: 32474387
[TBL] [Abstract][Full Text] [Related]
38. 17,20S(OH)
Brown Lobbins ML; Scott IO; Slominski AT; Hasty KA; Zhang S; Miller DD; Li W; Kim TK; Janjetovic Z; Patel TS; Myers LK; Postlethwaite AE
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445632
[TBL] [Abstract][Full Text] [Related]
39. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains.
Yamamoto T; Kuroda M; Nishioka K
Arch Dermatol Res; 2000 Nov; 292(11):535-41. PubMed ID: 11194891
[TBL] [Abstract][Full Text] [Related]
40. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice.
Kimura M; Kawahito Y; Hamaguchi M; Nakamura T; Okamoto M; Matsumoto Y; Endo H; Yamamoto A; Ishino H; Wada M; Omoto A; Tsubouchi Y; Kohno M; Yoshikawa T
Biomed Pharmacother; 2007 May; 61(4):222-8. PubMed ID: 17147981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
